NCT01782742View on ClinicalTrials.gov

Bexarotene Amyloid Treatment for Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

December 31, 2014

Conditions
Alzheimer's Disease
Interventions
DRUG

Bexarotene

Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo

DRUG

Placebo

Trial Locations (1)

89106

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas

All Listed Sponsors
lead

The Cleveland Clinic

OTHER

NCT01782742 - Bexarotene Amyloid Treatment for Alzheimer's Disease | Biotech Hunter | Biotech Hunter